Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected ...
BUT for many people and mainstream communities, that was considered a 'weird' or 'rock and roll character' kind of presentation. People would often openly stare ... I now have my phone that I can use ...
Japan’s economy grew at an annual rate of 2.9%, slower than the earlier report for 3.1% growth, in the April-June period, boosted by better wages and spending, revised government data ...